介入性心臟病学和周边血管器械市场：按产品类型、应用、最终用户和地区划分，2024-2031 年

介入性心臟病学和周边血管器械市场评估 - 2024-2031

全球心血管疾病的增加增加了对微创治疗的需求。特别是在已开发国家，人口老化和心臟病和血管疾病发病率较高需要先进的医疗干预措施，预计2024年市场发展将超过240.8亿美元，并预计到2031年将增长。 436.4亿美元。

此外，持续的技术进步，例如药物洗脱支架、生物可吸收血管支架和新的基于导管的技术的开发，正在提高这些手术的功效和安全性。不断上涨的医疗保健成本以及人们对心血管疾病早期检测和治疗益处的认识不断提高，正在推动市场成长，预计 2024 年至 2031 年复合年增长率约为 8.51%。

介入性心臟病学和周边血管器械市场定义/概述

介入性心臟病学和周边血管装置是专门的医疗器械和植入物，用于诊断和治疗影响心臟血管和周边动脉的疾病。支架、导管、球囊和导引线是用于治疗冠状动脉疾病、週边动脉疾病和其他血管疾病的微创手术中使用的装置。使用这些设备对于恢復血流而无需进行开放性手术、降低心臟病发作风险和改善患者预后至关重要。由于技术进步、世界人口老化以及心血管疾病盛行率的增加，这个市场的未来充满希望。持续的技术创新，例如生物可吸收支架和药物洗脱技术的开发，以及新兴市场医疗保健基础设施的扩展，预计将推动这些设备的全球成长和采用。

对微创治疗的需求不断增长将推动介入性心臟病学和周边血管器械市场？

对微创手术的需求不断增长预计将推动介入性心臟病学和周边血管器械市场。与传统的开放性手术相比，使用支架、球囊和导管等微创技术具有许多优势，包括更快的恢復时间、更短的住院时间和更低的併发症发生率。由于心血管疾病仍然是全球死亡的主要原因，医疗保健产业越来越依赖侵入性较小的先进手术来改善患者的治疗结果。这些手术在慢性心臟病常见的已开发国家的老年人中尤其受欢迎。

2024 年 6 月，美敦力 (Medtronic) 获得 FDA 核准用于治疗週边动脉疾病的新型微创球囊导管。该设备能够在对周围组织影响最小的情况下进行精确治疗，凸显了血管治疗中非侵入性解决方案的成长趋势。 2024年5月，Boston scientific也推出了最新的药物洗脱支架。该支架旨在减少冠状动脉再狭窄，并为心臟直视手术提供更安全、更有效的替代方案。

2024 年 3 月，欧洲药品管理局 (EMA) 意识到快速获得救生技术的迫切需求，宣布了新的法规，以加快微创心血管设备的审批流程。这些政策旨在鼓励更多企业在介入性心臟病学领域进行创新。总体而言，随着世界各地的医疗保健系统优先考虑患者安全和成本效益，对微创手术的需求预计将推动介入性心臟病学和周边血管设备市场的成长。

先进医疗设备的高成本是否会阻碍介入性心臟病学和周围血管设备市场的成长？

先进医疗设备的高成本限制了介入性心臟病学和周边血管设备市场的成长。这些医疗器材包括药物洗脱支架、生物可吸收血管支架和先进导管等尖端技术，通常价格昂贵，因为它们需要广泛的研究和开发以及监管审批流程。这可能会减少获得这些医疗设备的机会，特别是在卫生预算有限且患者自付费用过高的发展中国家。因此，在成本敏感的市场中，这些先进设备的采用可能会被推迟。

高成本也会影响医疗保健提供者，他们必须权衡使用尖端技术的好处与机构的财务限制。医院和诊所，特别是在公共卫生系统和报销率较低的地区，可能面临预算限制，限制其投资新的昂贵设备的能力。因此，患者接受的医疗服务品质可能因地理位置或社会经济地位而存在差异，这可能会阻碍整体市场的成长。

此外，先进医疗设备的高成本会抑制产业创新。如果公司认为成本问题会限制产品市场，他们可能不愿意投资新技术的开发。因此，重点可能是现有设备的渐进式改进，而不是突破性创新。从长远来看，先进设备的高成本可能会阻碍广泛采用最有效和创新的治疗方法，从而限制介入性心臟病学和周边血管设备市场的成长潜力。

目录

第一章简介

• 市场定义
• 市场区隔
• 调查方法

第 2 章执行摘要

• 主要发现
• 市场概览
• 市场亮点

第三章市场概述

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场阻碍因素
• 市场机会
• 波特五力分析

第 4 章介入性心臟病学和周边血管器械市场：按产品类型

• 冠状动脉支架
• 药物洗脱支架
• 裸金属支架
• 生物可吸收支架
• 导管
• 导丝
• 气球
• 斑块切除装置
• 慢性完全阻塞 (CTO) 装置
• 牙菌斑矫正装置
• 栓塞预防装置
• 其他

第 5 章介入性心臟病学和周边血管器械市场：按应用分类

• 冠状动脉疾病
• 週边动脉疾病
• 其他

第 6 章介入性心臟病学和周边血管器械市场：按最终用户划分

• 医院
• 门诊手术中心
• 其他

第七章区域分析

• 北美
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东/非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章市场动态

• 市场推动因素
• 市场阻碍因素
• 市场机会
• 新冠肺炎 (COVID-19) 对市场的影响

第九章竞争态势

• 主要公司
• 市占率分析

第十章公司简介

• Abbott Laboratories
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C.R. Bard（BD）
• Cardinal Health Inc.
• Cook Medical
• Koninklijke Philips N.V.
• Medtronic plc
• Teleflex Inc.
• Terumo Group
• W. L. Gore & Associates Inc.

第 11 章市场前景与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第12章附录

• 缩写列表
• 来源与参考文献

Interventional Cardiology and Peripheral Vascular Devices Market Valuation - 2024-2031

The rising global prevalence of cardiovascular diseases is driving up demand for minimally invasive procedures. The aging population, particularly in developed countries, is contributing to a higher incidence of heart and vascular diseases, necessitating advanced medical interventions evolving the market growth surpassing USD 24.08 Billion in 2024 and reachUSD 43.64 Billion by 2031.

Furthermore, ongoing technological advancements, such as the development of drug-eluting stents, bioresorbable vascular scaffolds, and novel catheter-based technologies, improve the efficacy and safety of these procedures. Increasing healthcare spending and growing awareness of the benefits of early detection and treatment of cardiovascular diseases help to drive market growth is expected to grow at aCAGR of about 8.51% from 2024 to 2031.

Interventional Cardiology and Peripheral Vascular Devices Market: Definition/ Overview

Interventional cardiology and peripheral vascular devices are specialized medical instruments and implants used to diagnose and treat conditions affecting the heart's blood vessels and peripheral arteries. Stents, catheters, balloons, and guidewires are among the devices used in minimally invasive procedures to treat coronary artery disease, peripheral artery disease, and other vascular disorders. The use of these devices is critical for restoring blood flow, lowering the risk of heart attack, and improving patient outcomes without the need for open surgery. The future of this market looks promising, thanks to technological advancements, an aging global population, and an increasing prevalence of cardiovascular diseases. Continued innovation, such as the development of bioresorbable stents and drug-eluting technologies, while expanding healthcare infrastructure in emerging markets are expected to drive the growth and adoption of these devices globally.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Demand for Minimally Invasive Procedures Propel the Interventional Cardiology And Peripheral Vascular Devices Market?

The growing demand for minimally invasive procedures is expected to propel the interventional cardiology and peripheral vascular devices market. In comparison to traditional open surgeries, minimally invasive techniques, such as the use of stents, balloons, and catheters, provide numerous advantages, including shorter recovery times, shorter hospital stays, and lower complication rates. As cardiovascular diseases remain a leading cause of death worldwide, the healthcare industry is increasingly relying on advanced, less invasive procedures to improve patient outcomes. These techniques are particularly popular among the elderly in developed countries, where chronic heart disease is common.

In June 2024, Medtronic received FDA approval for a new minimally invasive balloon catheter used to treat peripheral artery disease. This device enables precise treatment with minimal impact on surrounding tissue, highlighting the growing trend of non-invasive solutions in vascular care. In May 2024, Boston Scientific also introduced its latest drug-eluting stent, which is intended to reduce restenosis in coronary arteries while providing a safer and more effective alternative to open-heart surgery.

In March 2024, the European Medicines Agency (EMA) announced new regulatory initiatives to speed up the approval process for minimally invasive cardiovascular devices, recognizing the critical need for quicker access to life-saving technologies. These policies are intended to encourage more companies to innovate in the field of interventional cardiology. Overall, as healthcare systems around the world prioritize patient safety and cost-effectiveness, the demand for minimally invasive procedures is expected to fuel growth in the interventional cardiology and peripheral vascular devices market.

Will High Cost of Advanced Medical Devices Hinder the Growth of the Interventional Cardiology and Peripheral Vascular Devices Market?

The high cost of advanced medical devices limits the growth of the interventional cardiology and peripheral vascular devices market. These devices, which include cutting-edge technologies such as drug-eluting stents, bioresorbable vascular scaffolds, and advanced catheters, are often expensive due to the extensive research, development, and regulatory approval processes required. This can make these devices less accessible, especially in developing countries where healthcare budgets are limited and patients' out-of-pocket costs are prohibitively high. As a result, adoption of these advanced devices may be slower in markets where cost is an important consideration.

The high cost also affects healthcare providers, who must weigh the benefits of using cutting-edge technologies against their institutions' financial constraints. Hospitals and clinics may face budgetary constraints that limit their ability to invest in costly new devices, particularly in public healthcare systems or in areas with lower insurance reimbursement rates. This can result in disparities in the quality of care available to patients based on their geographical location or socioeconomic status, potentially impeding overall market growth.

Furthermore, the high cost of advanced medical devices can stifle innovation in the industry. Companies may be hesitant to invest in the development of new technologies if they believe the market for these products is constrained by cost concerns. This could result in an emphasis on incremental improvements to existing devices rather than ground-breaking innovations. In the long run, the high cost of advanced devices may act as a barrier to widespread adoption of the most effective and innovative treatments, limiting the growth potential of the interventional cardiology and peripheral vascular devices market.

Category-Wise Acumens

Will Rising Demand for Drug-Eluting Stents (DES) Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The increasing demand for drug-eluting stents (DES) is expected to drive significant growth in the interventional cardiology and peripheral vascular devices market. DES are becoming dominant due to their effectiveness in preventing restenosis, which is the re-narrowing of arteries following stent placement. These stents are coated with medication that is slowly released to reduce inflammation and the likelihood of artery reblockage, making them a better option than bare-metal stents. The benefits of DES, such as improved patient outcomes and fewer repeat procedures, are consistent with the growing global emphasis on effective and long-lasting cardiovascular treatments.

In June 2024, the European Medicines Agency (EMA) issued new guidelines to expedite the approval process for advanced cardiovascular devices, including DES. This move is intended to improve patients' access to innovative treatments throughout Europe. In May 2024 In the United States, the Food and Drug Administration (FDA) announced an initiative to increase funding for clinical trials examining the efficacy of DES in diverse populations, demonstrating a commitment to advancing the development and accessibility of these critical devices. These regulatory actions highlight the importance of DES in the cardiovascular market and support its continued expansion.

Chronic Total Occlusion (CTO) Devices are the fastest-growing segment of the market. The increasing prevalence of complex coronary artery disease, as well as technological advancements that improve the success rates of CTO procedures, are driving this growth. CTO devices are intended to treat long-term blockages in coronary arteries that have proven resistant to conventional treatments. The development of more effective and less invasive CTO devices is accelerating their adoption, reflecting a larger trend toward better solutions for difficult vascular conditions.

Will Rising Prevalence of Coronary Artery Diseases Dominate the Interventional Cardiology And Peripheral Vascular Devices Market?

Rising incidences of coronary artery disease (CAD) are expected to initiate its dominance in the interventional cardiology and peripheral vascular devices market. CAD is one of the most common cardiovascular diseases in the world, owing primarily to rising risk factors such as aging populations, unhealthy lifestyles, and high obesity and diabetes rates. As CAD remains a leading cause of morbidity and mortality, there is a steady and growing demand for advanced medical devices designed to treat it. These devices, which include drug-eluting stents, coronary balloons, and advanced catheter systems, are critical for managing and alleviating the effects of CAD. The consistently high demand for these technologies demonstrates their market dominance.

In June 2024, the US Centers for Disease Control and Prevention (CDC) announced a new initiative aimed at lowering the incidence of cardiovascular disease by improving access to innovative interventional technologies. This initiative includes funding for hospitals to acquire advanced CAD treatment devices as well as enhanced healthcare provider training. Furthermore, in May 2024, the European Society of Cardiology (ESC) updated its guidelines to emphasize the use of cutting-edge interventional devices in CAD management, reflecting a growing recognition of the importance of these technologies in improving patient outcomes. These developments highlight the importance of CAD in driving market trends, as well as the ongoing focus on improving treatment options for this common condition.

Peripheral Artery Disease (PAD) is the most rapidly growing application segment. PAD's rapid growth is attributed to an aging population, rising diabetes rates, and increased awareness of the condition. PAD, which affects blood flow to the limbs, is becoming more common as lifestyle risk factors increase. Advances in treatment technologies, such as new-generation balloon catheters and atherectomy devices designed specifically for PAD, are driving market growth in this area. The emphasis on improving patient outcomes and expanding treatment options for PAD is fueling this segment's rapid growth.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The advanced healthcare infrastructure in North America is a major driver of the interventional cardiology and peripheral vascular devices market. This region, with its well-established healthcare systems, cutting-edge medical facilities, and high healthcare expenditure, is an ideal environment for the adoption of advanced medical technologies. The presence of leading healthcare institutions and research centers promotes innovation and early adoption of new cardiovascular devices, which are essential for treating heart disease and peripheral vascular conditions. As cardiovascular diseases continue to be the leading cause of death in North America, the demand for these devices grows, driven by the need for effective and minimally invasive therapies.

The United States government has also played an important role in this development. In April 2024, the Centers for Medicare and Medicaid Services (CMS) implemented new reimbursement policies for advanced cardiovascular procedures, making these life-saving interventions more accessible to a larger patient population. This policy shift is expected to increase the adoption of interventional cardiology and peripheral vascular devices in North America, bolstering the region's global market leadership. North America's strong healthcare system, government support, and continuous innovation position it as a market leader.

Will Increasing Incidence of Cardiovascular Conditions in Asia-Pacific Propel the Interventional Cardiology and Peripheral Vascular Devices Market?

The rising prevalence of cardiovascular diseases in Asia-Pacific is expected to drive rapid growth of this region in the interventional cardiology and peripheral vascular devices market. The prevalence of cardiovascular diseases in Asia-Pacific is rapidly increasing, owing to factors such as aging populations, unhealthy diets, sedentary lifestyles, and rising hypertension and diabetes rates. This increase in cardiovascular conditions is driving up demand for advanced medical devices that can effectively treat and manage these diseases, particularly through minimally invasive procedures. As a result, Asia-Pacific's interventional cardiology and peripheral vascular device markets are expected to grow significantly.

In June 2024, Medtronic announced that it had expanded its operations in India and China, two of Asia-Pacific's largest markets, to increase the availability of its most recent stents and balloon catheters. This move aims to meet the growing demand for cardiovascular treatments in these countries, where the prevalence of heart disease is rapidly increasing. Similarly, in July 2024, Boston Scientific launched a new series of drug-eluting stents in the Asia-Pacific market, specifically designed to meet the region's unique patient needs. These developments emphasize the importance of the Asia-Pacific market for major medical device manufacturers, as well as the region's growing role in the global healthcare landscape.

Asia-Pacific countries are taking proactive measures to address the rising cardiovascular disease burden. For instance, in May 2024, the Chinese government announced a new initiative to improve heart disease prevention and treatment using advanced medical technologies. This initiative includes financial incentives for hospitals to purchase cutting-edge interventional cardiology devices, as well as training programs for healthcare professionals to improve their skills in using these devices. Similarly, in April 2024, the Indian government announced that it would expand its National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), with a focus on increasing access to life-saving cardiovascular interventions. These government efforts are expected to increase the adoption of interventional cardiology and peripheral vascular devices in Asia-Pacific, driving significant market growth.

Competitive Landscape

The competitive landscape of the interventional cardiology and peripheral vascular devices market is characterized by a mix of emerging players, regional manufacturers, and specialized companies focusing on niche segments. These competitors are leveraging innovative technologies and strategic partnerships to gain market share, particularly in areas like drug-eluting stents, atherectomy devices, and bioresorbable vascular scaffolds. Companies are also increasingly focusing on developing cost-effective solutions to cater to price-sensitive markets, particularly in emerging economies. Additionally, the market sees continuous product launches and FDA approvals, with smaller firms often introducing novel devices that address specific clinical needs, thus intensifying competition.

Some of the prominent players operating in the interventional cardiology and peripheral vascular devices market include:

Abbott Laboratories

Braun Melsungen AG

Biotronik SE & Co. KG

Boston Scientific Corporation

R. Bard (BD)

Cardinal Health, Inc.

Cook Medical, Koninklijke Philips N.V.

Medtronic plc

Teleflex, Inc.

Terumo Group

L. Gore & Associates, Inc.

Latest Developments

In May 2024, Abbott introduced a new bioresorbable stent in Europe, marking a significant step forward in interventional cardiology. The stent is intended to dissolve gradually, minimizing the long-term complications associated with traditional metal stents.

In April 2024, Terumo introduced a new peripheral guidewire in Japan with the goal of improving intervention precision in complex vascular cases. This product launch is part of Terumo's strategy to broaden its offerings in the peripheral vascular device market.

In January 2024, BD received CE mark approval for its most recent vascular access device, which includes advanced antimicrobial technology to reduce infection risks during interventional procedures. This development demonstrates BD's commitment to innovation in the peripheral vascular space.

In February 2024, Cardinal Health introduced a new line of vascular closure devices in the United States, designed to reduce bleeding complications following interventional procedures. This product line is intended for hospitals seeking cost-effective and efficient closure solutions.

In March 2022, Philips announced the acquisition of a leading vascular imaging software firm, expanding its image-guided therapy portfolio. This acquisition is expected to help Philips improve its capabilities in both interventional cardiology and peripheral vascular interventions.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Interventional Cardiology And Peripheral Vascular Devices Market, By Product Type

• Coronary Stents
• Drug-Eluting Stents
• Bare-Metal Stents
• Bioabsorbable Stents
• Catheters
• Guidewires
• Balloons
• Atherectomy Devices
• Chronic Total Occlusion (CTO) Devices
• Plaque Modification Devices
• Embolic Protection Devices
• Others

5. Interventional Cardiology And Peripheral Vascular Devices Market, By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Others

6. Interventional Cardiology And Peripheral Vascular Devices Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C.R. Bard (BD)
• Cardinal Health Inc.
• Cook Medical
• Koninklijke Philips N.V.
• Medtronic plc
• Teleflex Inc.
• Terumo Group
• W. L. Gore & Associates Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References